The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic ...

Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...

Shawn Kwatra, MD, FAAD, physician scientist at the University of Maryland Medical System, presented data at the American Academy of Dermatology 2025 annual conference on the rapid efficacy of topical ...

OPZELURA (ruxolitinib cream) has shown strong market growth, driven by increasing adoption in dermatological conditions like vitiligo and atopic dermatitis. Its unique positioning as the first ...

Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy ageing, is pleased to announce that its topical ...

Discover a study that aimed to compare the effects of antimicrobial–corticosteroid combination therapy with corticosteroid ...

Atopic dermatitis (eczema) is a chronic skin condition involving patches of dry, inflamed, and itchy skin. It can affect both children and adults. Various treatments can help manage symptoms.

Clinical phenotypes of atopic dermatitis can vary greatly based on skin color and can make atopic dermatitis difficult to diagnose.